Observation Of The Clinical Effect Of Intravitreous Injection Of Triamcinolone Acetonide And Ranibizumab For Wet AMD

Objective:To evaluate the clinical efficacy of triamcinolone acetonide and ranibizumab vitreous cavity injection in exudative age-related macular degeneration.Methods:42people who accepted intravitreal injection of triamcinolone acetonide and ranibizumab to Xinjiang Medical University are included into the study.24cases treat with triamcinolone acetonide and18cases with ranibizumab from february,2012to august,2013. Compare of BCVA(Best Corrected Visual Acuity),FFA(Fundus fluorescence angiography), OCT(Optical coherence tomography)changes and complications of the two groups. Results:Visual acuity:1,3,6months after surgery,The vision of the average increase of triamcinolone acetonide group improve from0.10±0.05to0.17±0.07,0.24±0.08and0.23±0.08,P<0.05and ranibizumab group improve from0.10±0.05to0.17±0.07,0.24±0.08and0.23±0.08,In general,there were no statistically differences of BCVA for the two groups(P>0.05).FFA:Triamcinolone acetonide group(24eyes):12eyes CNV(choroidal neovascularization)lesions leakage decreased apparently,11eyes CNV lesions leakage no significant change1eye lesions increases.Ranibizumab group(18eyes):10eyes CNV(choroidal neovascularization)lesions leakage decreased apparently,8eyes CNV lesions leakage no significant change no eye lesions increases.,there were no statistically differences(P>0.05)of FFA for the two groups.OCT:6months after surgery,triamcinolone acetonide group CST decreases from459.08±176.41(μm)to279.94±41.38(μm),CV decreases from11.37±2.40(mm3)to9.24±0.68(mm3),P<0.05.ranibizumab group CST decreases from379.61±111.81(μm)to286.61±46.18(μm),CV decreases from10.88±1.71(mm3)to9.34±0.89(mm3),P<0.05;but in general,there were no statistically differences of CST and CV for the two groups(P>0.05).Complications:There were no vitreous hemorrhage,retinal detachment endophthalmitis and other complications in the both two groups(P>0.05).Conclusion:the study showed two methods of treatment for wet age-related macular degeneration,that is,intravitreal injection of triamcinolone acetonide and ranibizumab,both of them are efficacy and safe in short time,but due to lack of clinic significance and the small samples,we can not drown a conclusion,further study is warranted.